Diabetes Trends

[Diabetes Trends] Novel Pharmacological Approaches to Treating Post-Prandial Hyperglycemia in Type 2 Diabetes

Overview

Overview
This webcast will review the barriers to treatment intensification and implement strategies to overcome them. The activity will also outline the rationale, safety, and efficacy of fixed-ratio GLP-1 RA +  basal insulin agents and discuss strategies for integrating them into treatment regimens for patients with T2DM.

Learning Objectives
  1. Recognize the barriers to treatment intensification and implement strategies to overcome them

  2. Outline the rationale, safety, and efficacy for fixed-ratio GLP-1 RA and basal insulin agents

  3. Integrate fixed-ratio GLP1 RA and basal insulin agents for the treatment of patients with T2DM

Activity Launch Date - 12/20/18
Expiration Date - 12/20/19

Diabetes Trends Information
The Diabetes Trends webcast series was adapted from a series of live programs presented in the Fall of 2018 in collaboration with the Nurse Practitioner Healthcare Foundation (NPHF). The goal of Diabetes Trends was to foster collaboration, share best practices and provide a forum for peer-to-peer interaction among primary care physicians and advanced practice providers who are actively engaged in the clinical care of diabetes patients.

This activity was originally presented as the third session in the Diabetes Trends series. Find other activities from this series on our website:
 

Supporter Acknowledgment Statement
This activity is supported by an independent educational grant from Merck.

Disclosure of Unlabeled Use
This educational activity may contain 
discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies.  It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes.  To that end, we welcome comments about how to better serve your needs.

Copyright Information
Copyright
© 2018 by Horizon CME.  All rights reserved.  No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME. 

Faculty

Umpierrez

Faculty
Guillermo E. Umpierrez, MD, FACP, FACE  
Professor of Medicine 
Emory University 
Director, Diabetes & Metabolism  
Grady Health Systems 
Atlanta, GA 

Faculty Bio
Guillermo E. Umpierrez, MD, FACP, FACE is professor of medicine in the division of endocrinology and clinical director of the Diabetes and Metabolism Center at Emory University School of Medicine and director the diabetes and endocrinology section and clinical research unit at Grady Memorial Hospital, Atlanta, GA.

Dr. Umpierrez is the recipient of numerous teaching awards for Best Clinical Teacher and Best mentor of Endocrine Fellows and Junior Faculty at Emory University, as well as national awards from the ACP, AACE and ADA. He is a member of AACE Diabetes Scientific Council and Board of Directors of AACE. Chair of the Global Task Force and member of the Endocrine Society Council, and member of the ADA Professional Practice Recommendation Committee. He is the Editor-in-Chief of the BMJ Open Diabetes Research & Care and the Editor-in-Chief of the ADA Medical Management of Diabetes clinical series. He has published more than 260 scientific manuscripts and book chapters and has presented over 250 abstracts at national and international scientific meetings.
 
Faculty Disclosure Statement
Dr. Umpierrez has served on an Advisory Board for Intarcia, Janssen and Sanofi. Funds for Contracted Research have been provided to his institution Emory University from AstraZeneca, Merck, Novo Nordisk and Sanofi. 

Planning Committee & Non-faculty Contributors Disclosure Statement
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose in the last 12 months. 

Learner Assurance Statement
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

Accreditation

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation
Horizon CME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How To Claim Credit

  • Read the learning objectives and faculty disclosures
  • Complete the Pre-test
  • Participate in the activity
  • Complete the Post-test 
  • Complete Final Evaluation